BSE Live
Dec 19, 16:01Prev. Close
1279.60
Open Price
1272.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 19, 15:55Prev. Close
1280.00
Open Price
1277.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1278.20 (345)
| Balance Sheet of Dr Reddys Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 85.20 | 85.10 | 84.90 | 84.80 | 84.60 | |
| Total Share Capital | 85.20 | 85.10 | 84.90 | 84.80 | 84.60 | |
| Reserves and Surplus | 9,767.90 | 7,780.10 | 6,284.20 | 4,904.20 | 3,947.30 | |
| Total Reserves and Surplus | 9,767.90 | 7,780.10 | 6,284.20 | 4,904.20 | 3,947.30 | |
| Total Shareholders Funds | 9,853.10 | 7,865.20 | 6,369.10 | 4,989.00 | 4,031.90 | |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 1,431.50 | 2,075.50 | 1,265.90 | 1,641.90 | 537.20 | |
| Deferred Tax Liabilities [Net] | 140.70 | 124.10 | 107.00 | 19.10 | 99.90 | |
| Other Long Term Liabilities | 273.30 | 118.10 | 35.00 | 49.50 | 56.80 | |
| Long Term Provisions | 77.90 | 56.30 | 51.40 | 33.30 | 28.80 | |
| Total Non-Current Liabilities | 1,923.40 | 2,374.00 | 1,459.30 | 1,743.80 | 722.70 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 2,185.70 | 2,060.70 | 1,898.60 | 1,588.80 | 1,831.90 | |
| Trade Payables | 867.30 | 893.20 | 965.70 | 756.60 | 634.50 | |
| Other Current Liabilities | 2,624.40 | 2,020.80 | 2,120.40 | 1,749.20 | 1,328.90 | |
| Short Term Provisions | 1,143.90 | 815.70 | 674.10 | 496.80 | 413.20 | |
| Total Current Liabilities | 6,821.30 | 5,790.40 | 5,658.80 | 4,591.40 | 4,208.50 | |
| Total Capital And Liabilities | 18,597.80 | 16,029.60 | 13,487.20 | 11,324.20 | 8,963.10 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 4,183.70 | 3,749.60 | 3,141.60 | 2,573.20 | 2,326.60 | |
| Intangible Assets | 1,193.30 | 891.20 | 909.00 | 838.50 | 1,058.90 | |
| Capital Work-In-Progress | 529.00 | 638.80 | 565.30 | 708.50 | 575.20 | |
| Fixed Assets | 5,906.00 | 5,279.60 | 4,615.90 | 4,120.20 | 3,960.70 | |
| Non-Current Investments | 145.60 | 0.40 | 0.40 | 0.90 | 0.90 | |
| Deferred Tax Assets [Net] | 245.00 | 191.70 | 174.20 | 134.00 | 122.40 | |
| Long Term Loans And Advances | 418.10 | 232.20 | 84.80 | 70.10 | 64.10 | |
| Other Non-Current Assets | 6.40 | 0.00 | 20.90 | 0.00 | 0.00 | |
| Total Non-Current Assets | 6,721.10 | 5,703.90 | 4,896.20 | 4,325.20 | 4,148.10 | |
| CURRENT ASSETS | ||||||
| Current Investments | 2,102.20 | 1,066.40 | 196.60 | 207.00 | 0.00 | |
| Inventories | 2,569.90 | 2,418.80 | 2,170.70 | 1,943.30 | 1,599.20 | |
| Trade Receivables | 4,101.20 | 3,325.30 | 3,180.40 | 2,536.80 | 1,761.10 | |
| Cash And Cash Equivalents | 1,872.40 | 2,300.60 | 2,017.10 | 1,606.10 | 575.10 | |
| Short Term Loans And Advances | 1,074.70 | 1,098.90 | 925.60 | 662.90 | 828.40 | |
| OtherCurrentAssets | 156.30 | 115.70 | 100.60 | 42.90 | 51.20 | |
| Total Current Assets | 11,876.70 | 10,325.70 | 8,591.00 | 6,999.00 | 4,815.00 | |
| Total Assets | 18,597.80 | 16,029.60 | 13,487.20 | 11,324.20 | 8,963.10 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 886.50 | 693.40 | 403.80 | 812.20 | 139.30 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 55.87 | 55.87 | 55.87 | 55.87 | 55.87 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 258.60 | 2.30 | 2.50 | 2.50 | 3.30 | |
| Non-Current Investments Unquoted Book Value | 7.10 | 7.10 | 7.10 | 7.10 | 7.10 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 1,076.20 | 201.00 | 208.00 | 0.00 | |
| Current Investments Unquoted Book Value | 2,142.20 | 0.00 | 0.00 | 0.00 | 0.00 |
15.12.2025
12.12.2025
25.11.2025
11.11.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz